Pegvaliase for treating phenylketonuria [ID1110]
Awaiting development [GID-TA10345] Expected publication date: TBC
Search results
221 results
-
-
Luspatercept for treating anaemia in non-transfusion dependent beta-thalassaemia [ID3870]
Awaiting development [GID-TA10909] Expected publication date: TBC
-
Test347
Awaiting development [GID-TA10949] Expected publication date: TBC
-
Danicopan with a C5 inhibitor for treating paroxysmal nocturnal haemoglobinuria in people with extravascular haemolysis ID 5088
Awaiting development [GID-TA10980] Expected publication date: TBC
-
Teplizumab for delaying the onset of type 1 diabetes in people 8 years and over at risk of developing the condition TS ID 10753
Awaiting development [GID-TA10981] Expected publication date: TBC
-
Abatacept for treating active idiopathic inflammatory myopathies TS ID 10095
Awaiting development [GID-TA10993] Expected publication date: TBC
-
Sacituzumab govitecan for treating unresectable metastatic urothelial cancer TS ID 10707
Awaiting development [GID-TA11009] Expected publication date: TBC
-
Olaparib for maintenance treatment of BRCA-negative platinum-sensitive relapsed ovarian, fallopian tube or primary peritoneal cancer TS ID 10749
Awaiting development [GID-TA10965] Expected publication date: TBC
-
Abatacept for preventing moderate to severe acute graft-versus-host disease after haematopoietic stem cell transplant in people 6 years and over TS ID 10679
Awaiting development [GID-TA10996] Expected publication date: TBC
-
Vedolizumab for treating chronic refractory pouchitis after surgery for ulcerative colitis TS ID 10720
Awaiting development [GID-TA10984] Expected publication date: TBC
-
Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma TS ID 10503
Awaiting development [GID-TA11008] Expected publication date: TBC
-
Lenvatinib with pembrolizumab for untreated PD-L1-positive recurrent or metastatic squamous cell head and neck cancer TS ID 10502
Awaiting development [GID-TA11005] Expected publication date: TBC
-
Zolbetuximab with chemotherapy for untreated CLDN 18.2-positive HER2 negative unresectable advanced gastric or gastro-oesophageal junction cancer TS ID 10579
Awaiting development [GID-TA11003] Expected publication date: TBC
-
Tusamitamab ravtansine for previously treated CEACAM5-positive metastatic non-squamous non-small-cell lung cancer ID4061
Awaiting development [GID-TA11034] Expected publication date: TBC
-
Atezolizumab for adjuvant treatment of renal cell carcinoma with a high risk of metastasis [ID5101]
Awaiting development [GID-TA11000] Expected publication date: TBC
-
Concizumab for preventing bleeding episodes in haemophilia A or haemophilia B [ID5099]
Awaiting development [GID-TA10972] Expected publication date: TBC
-
Emicizumab for preventing bleeding episodes in people with mild or moderate haemophilia A [ID5098]
Awaiting development [GID-TA11013] Expected publication date: TBC
-
Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion-positive advanced non-small-cell lung cancer [ID5110]
Awaiting development [GID-TA11023] Expected publication date: TBC
-
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]
Awaiting development [GID-TA11018] Expected publication date: TBC
-
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID 5102]
Awaiting development [GID-TA11010] Expected publication date: TBC
-
Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer [ID 5113]
Awaiting development [GID-TA11025] Expected publication date: TBC
-
Zanubrutinib for treating relapsed or refractory marginal zone lymphoma [ID 5085]
Awaiting development [GID-TA10962] Expected publication date: TBC
-
Pembrolizumab for neoadjuvant and adjuvant treatment of resectable stage 2 to 3B non-small-cell lung cancer [ID 5094]
Awaiting development [GID-TA11002] Expected publication date: TBC
-
Pembrolizumab with enzalutamide for treating metastatic hormone-relapsed prostate cancer [ID 5103]
Awaiting development [GID-TA11004] Expected publication date: TBC
-
Pembrolizumab with lenvatinib for previously treated metastatic colorectal cancer [ID 5112]
Awaiting development [GID-TA11020] Expected publication date: TBC
-
Pembrolizumab with lenvatinib for treating EGFR, ALK or ROS1-negative metastatic non-small-cell lung cancer after a PD-1 or PD-L1 inhibitor and platinum-based chemotherapy [ID 5109]
Awaiting development [GID-TA11024] Expected publication date: TBC
-
Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica [ID 5105]
Awaiting development [GID-TA11016] Expected publication date: TBC
-
Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID 5092]
Awaiting development [GID-TA10994] Expected publication date: TBC
-
Rucaparib for maintenance treatment of newly diagnosed platinum-sensitive ovarian, fallopian tube or peritoneal cancer [ID 5100]
Awaiting development [GID-TA10999] Expected publication date: TBC
-
Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people 1 to 17 years [ID 5104]
Awaiting development [GID-TA11006] Expected publication date: TBC
-
Etrasimod for previously treated moderately to severely active ulcerative colitis [ID 5091]
Awaiting development [GID-TA10991] Expected publication date: TBC
-
Dupilumab for treating eosinophilic oesophagitis in people 12 years and over [ID 5107]
Awaiting development [GID-TA11017] Expected publication date: TBC
-
Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast cancer [ID 5072]
Awaiting development [GID-TA10960] Expected publication date: TBC
-
Talquetamab for treating relapsed or refractory multiple myeloma after 3 therapies [ID 5082]
Awaiting development [GID-TA10969] Expected publication date: TBC
-
Durvalumab for treating limited-stage small-cell lung cancer after chemoradiation [ID 5073]
Awaiting development [GID-TA10959] Expected publication date: TBC
-
Navitoclax with ruxolitinib for treating myelofibrosis when stem cell transplant is unsuitable [ID 5096]
Awaiting development [GID-TA11007] Expected publication date: TBC
-
Teclistamab for treating relapsed or refractory multiple myeloma after 3 therapies [ID 5087]
Awaiting development [GID-TA10968] Expected publication date: TBC
-
Durvalumab with BCG for treating high-risk non-muscle-invasive bladder cancer after resection of papillary tumours in people previously untreated with BCG [ID 5080]
Awaiting development [GID-TA10967] Expected publication date: TBC
-
Maribavir for cytomegalovirus infection after haematopoietic stem cell transplant [ID 5075]
Awaiting development [GID-TA10958] Expected publication date: TBC
-
Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID 5077]
Awaiting development [GID-TA10971] Expected publication date: TBC
-
Mepolizumab for treating chronic obstructive pulmonary disease (ID1237)
Awaiting development [GID-TA10239] Expected publication date: TBC
-
Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy ID1587
Awaiting development [GID-TA10519] Expected publication date: TBC
-
Nicardipine (Nicaplant) for aneurysmal subarachnoid haemorrhage patients undergoing aneurysm clipping TS ID 10593
Awaiting development [GID-TA10957] Expected publication date: TBC
-
Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]
Awaiting development [GID-TA10723] Expected publication date: TBC
-
LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]
Awaiting development [GID-TA10728] Expected publication date: TBC
-
Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853]
Awaiting development [GID-TA10747] Expected publication date: TBC
-
Durvalumab with tremelimumab and chemotherapy for treating unresectable or advanced urothelial cancer [ID3855]
Awaiting development [GID-TA10748] Expected publication date: TBC
-
Netarsudil-latanoprost for previously treated open-angle glaucoma or ocular hypertension [ID1363]
Awaiting development [GID-TA10741] Expected publication date: TBC
-
Treprostinil for treating symptomatic chronic thromboembolic pulmonary hypertension [ID3926 ]
Awaiting development [GID-TA10821] Expected publication date: TBC
-
Remimazolam for sedation for people having diagnostic or therapeutic procedures [ID3758]
Awaiting development [GID-TA10720] Expected publication date: TBC